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Dear Editor,
Five-aminolevulinic acid (5-ALA)-derived fluorescence is ap-
proved for fluorescence-guided resections of malignant glio-
mas, relying on selective synthesis and accumulation of pro-
toporphyrin IX (PPIX) within malignant glioma cells [5].
However, the first use of fluorescence for brain tumour sur-
gery was in 1948 byG.E.Moore [3] using fluorescein sodium,
a strongly fluorescing and non-toxic (apart from rare anaphy-
laxis [2]) compound. In malignant brain tumours with their
inherent blood-brain barrier breakdown, fluorescein is extrav-
asated and might serve to mark tumours.
Today, fluorescein sodium is again under scrutiny [1, 4]
using a novel filter system by Zeiss (YELLOW 560) for the
microscope. This filter visualises fluorescein and allows good
background discrimination. Furthermore, fluorescein can be
injected any time and is low in cost. Nevertheless, its use in
brain tumour surgery is off-label and thus restricted to clinical
studies.
Little is known about the best timing of i.v. fluorescein
application before resection. Injecting fluorescein too early
might result in unspecific propagation with oedema, whereas
acute injections might be useful for detecting abnormally per-
fused tumour tissue. Levels in the blood will be high, espe-
cially with acute injections, leading to fluorescence of all per-
fused brain tissue. To our knowledge, such time-resolved in-
formation on the specificity of fluorescein are not available.
Therefore, we conducted a small pilot study using two timing
regimes in four patients pre-treated with 5-ALA (20 mg/kg,
Gliolan; medac, Wedel, Germany), comparing early (35 min
prior to durotomy, as previously described [4]) with acute
injections of fluorescein (4 mg/kg, Fluorescein Alcon 10 %;
Alcon, Freiburg, Germany). We used a Leica M530 OH6
(Leica Microsystems, Heerbrugg, Switzerland) equipped with
a FL400 filter, freely interchangeable with an experimental
band pass filter system for detecting fluorescein fluorescence
without superimposed background information (Leica FL560)
and allowing simultaneous visualisation of both fluorophores.
An example of fluorescein application prior to opening of
the dura is given in the Fig. 1. This patient presented with a
secondary malignant glioma in the right fronto-temporal re-
gion with patchy contrast enhancement. PPIX fluorescence
was predominantly noted in one area, shining through the
cortex, and was patchier in other areas. Fluorescein was found
corresponding to porphyrin fluorescence, but was also visible
in the dura, the cerebrospinal fluid (CSF) and weakly through-
out the brain. After corticotomy fluorescein was found spread-
ing through the arachnoid space away from the lesion, corre-
sponding to regions of superficial coagulation for extending
the corticotomy, along the corticotomy margins and in blood.
In a second patient, a patient with recurrent low-grade gli-
oma, in whom fluorescein was given before opening of the
dura, fluorescence was found in the brain adjacent to the tu-
mour and in the dura itself. However, fluorescence appeared
patchy or missing in the macroscopically detectable tumour.
The tumour was not positive for 5-ALA fluorescence. At the
end of the resection, after tumour removal had been confirmed
by intra-operative ultrasound, diffuse green fluorescence was
observed along all resection margins. Biopsies taken from this
area were devoid of tumour.
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In a third case, a patient with temporal glioblastoma, we
attempted acute injection (Supplementary video) to determine
whether fluorescein would correspond to porphyrin fluores-
cence. Fluorescein was visible in normally perfused brain. In
the tumour cavity, fluorescein was in fact extravasated in the
region of gross and necrotic tumour, but was not or vaguely
visible in the marginal tumour. Blue light illumination for
PPIX showed the adjacent white matter to carry strong red
PPIX fluorescence, signifying tumour. We had a similar expe-
rience with a final patient after debulking of the main tumour
mass and acute injection.
Overall, we observed no clear value of fluorescein in our
small study, which we closed prematurely. Clearly, further
work elucidating optimal timing and dosing of fluorescein is
warranted.
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Fig. 1 White light (a) and PPIX image (b) of exposed cortex (proximal
perisylvian region) demonstrating patchy PPIX fluorescence shining
through the otherwise mostly unremarkable cortex. c Fluorescein image
after application of fluorescein prior to dura opening, as previously
described [4]. There is some indication of fluorescein fluorescence
corresponding to PPIX fluorescence. However, green fluorescence was
also observed in a CSF accumulation at the base of the Sylvian fissure,
less strongly throughout the entire cortex and in a small area of cortical
damage, presumably imposed during durotomy, is also visible. d and g
White light images after corticotomy; e and h corresponding PPIX
images; f and i corresponding fluorescein images showing unspecific
extravasation in the cortex after coagulation for corticotomy
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